Pharmaceutical

NephroDI Therapeutics and MSRD partner to develop therapy for NDI

NephroDI Therapeutics has signed a deal with the McQuade Center for Strategic Research and Development (MSRD) for the development of NDI-5001

Jun 23, 2023 - 20:00
NephroDI Therapeutics and MSRD partner to develop therapy for NDI
NephroDI Therapeutics has signed a deal with the McQuade Center for Strategic Research and Development (MSRD) for the development of NDI-5001
Read the original article

Tags:

Previous Article

FDA approves Duchenne gene therapy with hefty $3.2m price tag

Next Article

BMS and Eurofins invest in Indian pharma hubs Andhra Pradesh and Telangana

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Listen: Vertex’s polarizing data, Aduhelm’s adieu, & an FDA icon

Listen: Vertex’s polarizing data, Aduhelm’s adieu, & an...

Feb 1, 2024

STAT+: New obesity drugs are in the works trying to out-blockbuster Wegovy and Mounjaro

STAT+: New obesity drugs are in the works trying to out...

Sep 12, 2023

A rational design approach to RNA targeting could replace large-scale screening

A rational design approach to RNA targeting could repla...

Oct 6, 2024